Evidence map›Paper›PMID 36299423›Full record

ArticlebioRxiv : the preprint server for biology2022

Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2.

Panke Qu, John P Evans, Julia Faraone, Yi-Min Zheng, Claire Carlin, Mirela Anghelina, Patrick Stevens, Soledad Fernandez, Daniel Jones, Gerard Lozanski and 6 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 87 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Panke QuCenter for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA.
John P EvansCenter for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA.
Julia FaraoneCenter for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA.
Yi-Min ZhengCenter for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA.
Claire CarlinDepartment of Internal Medicine, Division of Cardiovascular Medicine, The Ohio State University, Columbus, OH 43210, USA.
Mirela AnghelinaDepartment of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, 43210, USA.
Patrick StevensDepartment of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, 43210, USA.
Soledad FernandezDepartment of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, 43210, USA.
Daniel JonesDepartment of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Gerard LozanskiDepartment of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Ashish PanchalDepartment of Emergency Medicine, The Ohio State University Wexner Medical Center, Columbus, USA.
Linda J SaifCenter for Food Animal Health, Animal Sciences Department, OARDC, College of Food, Agricultural and Environmental Sciences, The Ohio State University, Wooster, OH 44691, USA.
Eugene M OltzDepartment of Microbial Infection and Immunity, The Ohio State University, Columbus, OH 43210, USA.
Kai XuCenter for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA.
Richard J GuminaDepartment of Internal Medicine, Division of Cardiovascular Medicine, The Ohio State University, Columbus, OH 43210, USA.
Shan-Lu LiuCenter for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA.
The Ohio State University · USThe Ohio State University Wexner Medical Center · US

Funding

Project 3: Responding to Changing Serological and Viral Information around COVID-19 (RESPOND)U54CA260582 · NCI · OHIO STATE UNIVERSITY · PI MCALEARNEY, ANN SCHECK, OLTZ, EUGENE M · 2020 to 2024
$10.4M
The impact of vitamin A on the gut-mammary gland-secretory IgA axis during enteric viral infectionsR01HD095881 · NICHD · OHIO STATE UNIVERSITY · PI SAIF, LINDA J., VLASOVA, ANASTASIA NICKOLAEVNA · 2018 to 2022
$2.3M
NCI NIH HHS U54 CA260582NICHD NIH HHS R01 HD095881
6 · The paper itself

Abstract

Continued evolution of SARS-CoV-2 has led to the emergence of several new Omicron subvariants, including BQ.1, BQ. 1.1, BA.4.6, BF.7 and BA.2.75.2. Here we examine the neutralization resistance of these subvariants, as well as their ancestral BA.4/5, BA.2.75 and D614G variants, against sera from 3-dose vaccinated health care workers, hospitalized BA.1-wave patients, and BA.5-wave patients. We found enhanced neutralization resistance in all new subvariants, especially the BQ.1 and BQ.1.1 subvariants driven by a key N460K mutation, and to a lesser extent, R346T and K444T mutations, as well as the BA.2.75.2 subvariant driven largely by its F486S mutation. The BQ.1 and BQ.1.1 subvariants also exhibited enhanced fusogenicity and S processing dictated by the N460K mutation. Interestingly, the BA.2.75.2 subvariant saw an enhancement by the F486S mutation and a reduction by the D1199N mutation to its fusogenicity and S processing, resulting in minimal overall change. Molecular modelling revealed the mechanisms of receptor-binding and non-receptor binding monoclonal antibody-mediated immune evasion by R346T, K444T, F486S and D1199N mutations. Altogether, these findings shed light on the concerning evolution of newly emerging SARS-CoV-2 Omicron subvariants.

Identifiers

PMID36299423
PMCPMC9603827
OpenAlexW4306964313

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.